EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The economics of heart failure care

Chen Wei, Paul A Heidenreich, Alexander T Sandhu

Progress in Cardiovascular Diseases · 2024-01 · 82 · 90-101

DOI: 10.1016/j.pcad.2024.01.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2024-01. Verfasst von Chen Wei und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Stanford University School of Medicine, United States of America. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Defibrillators, Implantable. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, American Heart Association, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) poses a significant economic burden in the US, with costs projected to reach $70 billion by 2030. Cost-effectiveness analyses play a pivotal role in assessing the economic value of HF therapies. In this review, we overview the cost-effectiveness of HF therapies and discuss ways to improve patient access. Based on current costs, guideline directed medical therapies for HF with reduced ejection fraction provide high economic value except for sodium-glucose cotransporter-2 inhibitors, which provide intermediate economic value. Combining therapy with the four pillars of medical therapy also has intermediate economic value, with incremental cost-effectiveness ratios ranging from $73,000 to $98,500/ quality adjusted life-years. High economic value procedures include cardiac resynchronization devices, implantable cardioverter-defibrillators, and coronary artery bypass surgery. In contrast, advanced HF therapies have previously demonstrated intermediate to low economic value, but newer data appear more favorable. Given the affordability challenges of HF therapies, additional efforts are needed to ensure optimal care for patients. The recent Inflation Reduction Act contains provisions to reform policy pertaining to drug price negotiation and out-of-pocket spending, as well as measures to increase access to existing programs, including the Medicare low-income subsidy. On a patient level, it is also important to encourage patient and physician awareness and discussions surrounding medical costs. Overall, a broad approach to improving available therapies and access to care is needed to reduce the growing clinical and economic morbidity of HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailureDefibrillators, ImplantableAgedHumansUnited StatesCost-Benefit AnalysisMedicare

Stichwörter der Autor:innen

Cost effectivenessFinancial toxicityHealth economicsHeart failurePrice transparency

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Stanford University School of Medicine, United States of America.
  • Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, United States of America; Palo Alto Veterans Affairs Healthcare System, Palo Alto, CA, United States of America.
  • Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, United States of America; Palo Alto Veterans Affairs Healthcare System, Palo Alto, CA, United States of America. Electronic…

Förderung

  • NHLBI NIH HHS
  • American Heart Association
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Wei, C., Heidenreich, P. A., & Sandhu, A. T. (2024). The economics of heart failure care. Progress in Cardiovascular Diseases, 82, 90-101. https://doi.org/10.1016/j.pcad.2024.01.010

Vancouver

Wei C, Heidenreich PA, Sandhu AT. The economics of heart failure care. Progress in Cardiovascular Diseases. 2024;82:90-101. doi:10.1016/j.pcad.2024.01.010

BibTeX
@article{Wei2024,
  author = {Wei, Chen and Heidenreich, Paul A and Sandhu, Alexander T},
  title = {The economics of heart failure care},
  journal = {Progress in Cardiovascular Diseases},
  year = {2024},
  volume = {82},
  pages = {90--101},
  doi = {10.1016/j.pcad.2024.01.010}
}
Kostenlos starten →